Muhammed Mustafa Atci
- Specialization: Clinical oncologist
- 14 years of experience
- Speaks:English, Turkish
- Online consultations: available
- Workplace: Turkey, Istanbul, İstinye University Liv Hospital Topkapı
- Member of the American Society of Clinical Oncology (ASCO) since 2018.
Dr. Muhammed Mustafa Atci is an Associate Professor of Medical Oncology at İstinye University, Liv Hospital Topkapı (2025–present). He previously served as Associate Professor and Education Coordinator at Prof. Dr. Cemil Taşcıoğlu City Hospital (2023–2025). He was also a Medical Oncologist there (2018–2021).
He has been a member of ASCO and the Turkish Society of Medical Oncology since 2018. He is the author or co-author of 19 peer-reviewed international papers on colon, breast, gastric, pancreatic, lung, thyroid, sarcoma, and colorectal cancers.
Notable works include a multicentre study on stage IIB colon cancer survival (Journal of Chemotherapy). He also studied the De Ritis ratio for lung metastasis in testicular cancer (Current Urology). His prognostic studies used PET/CT, MSI, lymph node ratio, and metabolic tumor volume.
Online consultation with Muhammed Mustafa Atci
Doctor's services
- Target therapy for lung cancer
- Chemotherapy for Sarcomas
- Chemotherapy for Brain Tumor
- Radioembolization for liver cancer
- Chemotherapy for esophageal carcinoma
- Chemotherapy for kidney cancer
- Chemotherapy for testicular cancer
- Chemotherapy for ovarian cancer
- Chemotherapy for uterine cancer
- Immunotherapy for breast cancer
- Immunotherapy for kidney cancer
- Immunotherapy for lung cancer
- Chemotherapy for colon cancer
- Chemotherapy for breast cancer
- Chemotherapy for pancreatic cancer
- Chemotherapy for stomach cancer
- Chemotherapy for uterine cancer
- Chemotherapy for gallbladder cancer
- Chemotherapy for lung cancer
- Chemotherapy for prostate cancer
- Immunotherapy for prostate cancer
- Hormone therapy for prostate cancer
- Chemotherapy for liver cancer
- Chemotherapy
- Chemotherapy for larynx cancer
- Hyperthermic Intraperitoneal Chemotherapy (HIPEC)
- Chemoembolization of the liver
- Immunotherapy with Keytruda (Pembolizumab)
- Immunotherapy
- Sarcoma Immunotherapy
- PET/CT
- Colonoscopy
- Angiography
- Biopsy
- MRI of one area
- Mammography
- Tumor Marker Blood Test
- Gastroscopy with biopsy
- Fibroscan
- CT of thoracic, abdominal and pelvic organs
- CT scan of the whole body
- PET-CT with Gallium 68(PSMA)
- Flash CT scan
- Whole-body MRI
- CT (computer tomography)
- MRI of the abdominal cavity
- Brain biopsy
- Cancer screening
- Brain MRI
- Immunohistochemistry
- PET-MRI
- Breast biopsy
- Lung biopsy
- PET-CT with Gallium 68 (DOTA)
- Brain MRI with contrast (FLAIR sequence)
- Kidney biopsy
- KRAS, NRAS,BRAF mutation testing
- Watson for Oncology
- Liver biopsy
- Pancreas biopsy
- PET-CT with Gallium 68 (DOTATATE)
- Thyroid biopsy
- Thyroid function tests (including T3, T4, TSH)
- Oncological Check-up for Man
- Online Consultation with Oncologist
- Comprehensive diagnosis of Сolorectal Pathology
- Testicular Biopsy
- Ovarian Biopsy
- Online Consultation with Hematologist
- MR Linac
- Mole mapping and digital dermoscopy for mole assessment
- Online Consultation with Dermatologist
- Chest X-Ray
- Online consultation with Surgeon
How are we doing?
Qualifications
Education
Doctor of Medicine (M.D.)
2003 – 2009
Istanbul University – Cerrahpaşa Faculty of Medicine, Turkey
Residency in Internal Medicine
2011 – 2015
University of Health Sciences – Istanbul Şişli Hamidiye Etfal Health Application and Research Center, Department of Internal Medicine, Turkey
Professional Experience
Internal Medicine Specialist
2015 – 2017
Tokat State Hospital, Turkey
Internal Medicine Specialist
2017 – 2018
Istanbul Haseki Training and Research Hospital, Turkey
Medical Oncologist
2018 – 2021
University of Health Sciences – Istanbul Prof. Dr. Cemil Taşcıoğlu City Health Application and Research Center, Department of Internal Medicine / Oncology Department, Turkey
Associate Professor of Medical Oncology & Education Coordinator
2023 – 2025
Ministry of Health – Prof. Dr. Cemil Taşcıoğlu City Hospital, Turkey
Education Coordinator for the Medical Oncology Sub-Branch
Associate Professor of Medical Oncology
2025 – Present
İstinye University, Liv Hospital Topkapı, Turkey
Memberships to Scientific Organizations
American Society of Clinical Oncology (ASCO) – Member since 2018
Turkish Society of Medical Oncology – Member since 2018
Articles Published in Peer-Reviewed International Journals
1. Atcı, M. M., Akagündüz, B., Demir, M., Arıkan, R., Ay Ersoy, S., Özer, M., Ayhan, M., Çil, İ., Demir, N., Özyurt, N., Karakaya, G., Çevik, G. T., Önder, A. H., Selvi, O., Sakin, A. (2023). The impact of adjuvant oxaliplatin and tumor sidedness on the overall survival of stage IIB colon cancer patients: a multicentre study. Journal of Chemotherapy.
2. Bozkurt, M., Aghalarov, S., Atcı, M. M., Selvi, O., Canat, H. L. (2022). A new biomarker for lung metastasis in non-seminomatous testicular cancer: De Ritis Ratio. Current Urology.
3. Dülgar, Ö., Öven, B. B., Atcı, M. M., Arıkan, R., Ay Ersoy, S., Ayhan, M., Selvi, O., Tataroğlu Özyükşeler, D., Bayram, E., Özcan, E., Yasin, A. İ., Gümüş, M. (2022). Is the benefit of using adjuvant capecitabine in patients with residual triple-negative breast cancer related to pathological response to neoadjuvant chemotherapy? Expert Review of Anticancer Therapy.
4. Akagündüz, B., Altın, Z., Atcı, M. M., Özer, M., Güven, D. C., Çil, İ., Özçiçek, F., Demirtaş, L., Düzgün, E., Gunderci, A., Arslan, Y. (2021). Assessment of abuse and related factors in older patients with cancer. Supportive Care in Cancer.
5. Akagündüz, B., Özer, M., Karaçin, C., Atcı, M. M., Yıldırım, H. Ç., Ünver, E. (2021). Impact of coronaphobia on treatment and follow-up compliance of cancer patients. Future Oncology.
6. Arıcı, S., Sağlampınar Karyağar, S., Uslu Erdemir, R., Çekin, R., Atcı, M. M., Güven, O., Karyağar, S., Cihan, Ş. (2021). The correlation between tumor markers and Ga-68 DOTA-TATE PET/CT findings in patients with advanced medullary thyroid cancer. Revista Española de Medicina Nuclear e Imagen Molecular.
7. Atcı, M. M., Gerede, Ç., Ay Ersoy, S., Ertürk, B., Seçmeler, Ş., Arıcı, S., Çekin, R., Yaşar, N., Can, O., Cihan, Ş., Gümüş, M. (2021). Clinical and pathological characteristics of patients with high-risk breast cancer based on BRCA mutation profiles: A retrospective study. European Journal of Breast Health.
8. Calm, A., Atcı, M. M., Aldemir, M. N., Akagündüz, B., Şahin, S., Arıcı, S., Seçmeler, Ş., Cihan, Ş. (2021). The prognostic value of postoperative lymph node ratio in neoadjuvant-treated gastric adenocarcinoma patients. Cureus.
9. Calm, A., Şahin, S., Sağlampınar Karyağar, S., Karyağar, S., Atcı, M. M., Akbörü, M. H., Cihan, Ş. (2021). The predictive value of baseline volumetric PET/CT parameters on treatment response and prognosis in locally advanced rectal cancer treated with neoadjuvant chemoradiotherapy. Journal of Gastrointestinal Cancer.
10. Arıcı, S., Şengiz Erhan, S., Geredeli, Ç., Atcı, M. M., Seçmeler, Ş., Çekin, R., Sakin, A., Cihan, Ş. (2021). The prognostic importance of microsatellite instability status in Turkish stage II and III gastric cancer patients who received adjuvant chemotherapy. International Journal of Hematology and Oncology.
11. Calm, A., Şahin, S., Atcı, M. M., Ayşegül, P., Yaşar, N., Geredeli, Ç., Aksaray, F., Cihan, Ş. (2021). The effect of different treatment modalities on survival in elderly patients with locally advanced non-small cell lung cancer. Pulmonology.
12. Ayşegül, P., Şahin, S., Abdullah, P., Atcı, M. M., Geredeli, Ç., Cihan, Ş. (2021). Effect of type 2 diabetes mellitus on survival in metastatic pancreatic cancer. Journal of Surgery and Medicine (JOSAM).
13. Akagündüz, B., Akın Telli, T., Yıldırım, H. Ç., Sezgin Göksu, S., Demir, N., Hafızoğlu, E., Özer, M., Çevik, G. T., Sakin, A., Göktaş, A. S., Şengül Samancı, N., Özyurt, N., Atcı, M. M., Ayhan, M., Turan, M., Sarıyar, N., Karaçin, C., Kılıçkap, S., Paydaş, S., Doğan, M. (2021). Factors affecting survival in retroperitoneal sarcomas treated with upfront surgery: A real-world study by Turkish Oncology Group. International Journal of Hematology and Oncology.
14. Calm, A., Şahin, S., Atcı, M. M., Yaşar, N., Demir, C., Geredeli, Ç., Sakin, A., Cihan, Ş. (2020). The effect of body mass index on treatment outcomes in patients with metastatic non-small cell lung cancer treated with platinum-based therapy. Nutrition and Cancer.
15. Ayşegül, P., Şahin, S., Abdullah, P., Atcı, M. M., Yaşar, N., Arıcı, S., Geredeli, Ç., Karataş, F., Cihan, Ş. (2020). Assessment of pre-treatment albumin-bilirubin grade in pancreatic cancer patients with liver metastases. Journal of BUON.
16. Abdullah, P., Süleyman, Ş., Ayşegül, P., Atcı, M. M., Serdar, A., Yaşar, N., Demir, C., Geredeli, Ç., Cihan, Ş. (2020). Factors affecting survival in operated pancreatic cancer; Does tumor localization have a significant effect on treatment outcomes? Northern Clinics of Istanbu.
17. Arıcı, S., Sağlampınar Karyağar, S., Karyağar, S., Geredeli, Ç., Çekin, R., Seçmeler, Ş., Atcı, M. M., Sakin, A., Cihan, Ş. (2020). The predictive role of metabolic tumor volume on non-response to neoadjuvant chemotherapy in patients with breast cancer. Journal of Oncology Pharmacy Practice.
18. Calm, A., Yılmaz, Y., Şahin, S., Atcı, M. M., Arıcı, S., Geredeli, Ç., Yaşar, N., Demir, C., Cihan, Ş. (2020). Factors affecting survival in esophageal squamous cell carcinoma: Single-center experience. Northern Clinics of Istanbul.
19. Calm, A., Şahin, S., Atcı, M. M., Yaşar, N., Geredeli, Ç., Arıbal, S., Alemdar, A., Karataş, F., Cihan, Ş. (2019). Factors affecting survival in patients with isolated liver-metastatic colorectal cancer treated with local ablative or surgical treatments for liver metastasis. Journal of BUON.
You may also be interested
Payment & Rewards
You don’t pay for our services
You make your payment directly at the clinic or to their official bank account.
Some clinics may require a deposit as a part of their policy.
Spread out your payments with installment options.
Earn rewards for referring friends to Bookimed.